Study study type PathologyT1T0Patientssample sizesROB Results

metastatic/advanced OC (mOC) - 1st line (L1) metastatic/advanced OC (mOC) - 1st line (L1)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
AGO-OVAR 2.29/ENGOT-ov34, 2024
  NCT03353831
RCTovarian cancer (OC)atezolizumabSocrecurrent ovarian, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after completing platinum-based chemotherapy or 3rd relapse285 / 289NA
inconclusive
  • inconclusive 17 % decrease in deaths (OS) (PE)
  • inconclusive 13 % decrease in progression or deaths (PFS) (PE)

mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population

versus placebo plus SoC
atezolizumab plus SoC
IMagyn-050 (all population), 2021
  NCT03038100
RCTmOC - L1 - all populationatezolizumab plus paclitaxel carboplatin and bevacizumalbplaceb plus paclitaxel carboplatin and bevacizumalbpatients with stage III or stage IV epithelial ovarian, fallopian tube, or primaryperitoneal cancer with either macroscopic residual disease or who will undergo neoadjuvant chemotherapy followed by interval surgery651 / 650low
inconclusive
  • inconclusive 4 % decrease in deaths (OS) (PE)
  • inconclusive 8 % decrease in progression or deaths (PFS) (PE)

mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive

versus placebo plus SoC
atezolizumab plus SoC
IMagyn-050 (PDL1 >1%), 2021
  NCT03038100
RCTmOC - L1 - PDL1 positiveatezolizumab plus paclitaxel carboplatin and bevacizumalbplaceb plus paclitaxel carboplatin and bevacizumalbpatients with stage III or stage IV epithelial ovarian, fallopian tube, or primaryperitoneal cancer with either macroscopic residual disease or who will undergo neoadjuvant therapy followed by interval surgery, PDL1 positive population391 / 393low
suggested
  • inconclusive 2 % decrease in deaths (OS) (PE)
  • suggested 20 % decrease in progression or deaths (PFS) (PE)